Skip to content
Back to BHC

Bausch Health Companies Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
6
Purchases
1
Sales
5
Purchase value
$15.63M
Sale value
$506.73K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Aimee J. LenarPresident, US Pharma
4Rule 10b5-1 plan disclosed
Filed Aug 20, 2026Period of report Aug 19, 20260000885590-26-000109
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 19, 2026
Common Shares, No Par ValueF136,827$7.03$258.89K334,853Direct
Filing footnotes · 1
  1. F1Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 21, 2026.
Open on SEC EDGAR
Frank D. LeeDirector
4Rule 10b5-1 plan disclosed
Filed May 20, 2026Period of report May 19, 20260000885590-26-000063
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 19, 2026
Common Shares, No Par ValueF124,456$5.43$132.80K49,339Direct
Filing footnotes · 1
  1. F1Represents shares of the Issuer's common stock, no par value, sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors.
Open on SEC EDGAR
Seana CarsonEVP, General Counsel
4Rule 10b5-1 plan disclosed
Filed Mar 3, 2026Period of report Feb 27, 20260000885590-26-000039
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 3, 2026
Common Shares, No Par ValueF54,420$5.77$25.50K616,761Direct
SaleMar 2, 2026
Common Shares, No Par ValueF26,856$5.78$39.63K776,076Direct
Filing footnotes · 5
  1. F1This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
  2. F2Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.
  3. F3This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
  4. F4Reflects the disposition in cash as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada) of 137,922 performance share unit awards originally granted to the Reporting Person under the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan on March 2, 2023, which, as previously reported on February 11, 2026, were earned, on February 9, 2026, upon certification by the Talent and Compensation Committee (the "Committee") of the Board of Directors of the Issuer of the level of achievement of the applicable performance metrics, but remained subject to service-based vesting. As disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 2, 2026, the Committee subsequently took action to provide for the payment of such earned performance share unit awards in cash rather than Issuer common stock upon vesting. The disposition in cash is exempt under Rule 16b-3(e).
  5. F5Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.
Open on SEC EDGAR
Seana CarsonEVP, General Counsel
4Rule 10b5-1 plan disclosed
Filed Feb 27, 2026Period of report Feb 25, 20260000885590-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 27, 2026
Common Shares, No Par ValueF38,388$5.95$49.91K809,258Direct
Filing footnotes · 3
  1. F1Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc.
  2. F2This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
  3. F3Represents shares of common stock sold in the open market pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 7, 2025.
Open on SEC EDGAR
Paulson & Co. Inc.10% owner
4
Filed Nov 28, 2025Period of report Nov 25, 20250001013594-25-001474
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 25, 2025
Common Stock, no par valueF12,500,000$6.25$15.63M73,255,869IndirectBy Managed Funds
Filing footnotes · 1
  1. F1Paulson & Co. ("Paulson") is the investment manager of certain investment funds (the "Funds"). John Paulson is the controlling person of Paulson. All securities reported on this Form 4 are owned by the Funds. Each of Paulson and John Paulson may be deemed an indirect beneficial owner of the securities, which are directly owned by the Funds. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the reporting person disclaims beneficial ownership of any securities reported herein, except to the extent that the reporting person has a pecuniary interest therein. This report shall not be deemed an admission by any person reporting on this Form 4 that such person, for purposes of Section 16 of the Act or otherwise, is the beneficial owner of any securities not directly owned by such reporting person.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.